Friday, October 21, 2011

New Drug from Sunshine Biopharma, Inc. (SBFM) to Play Critical Role in Fight against Cancer

It’s easy to forget that, in spite of periodic frustrations and disappointments, very real progress has been and continues to be made in the war against cancer. Decades of research have given us a much better understanding of how cancer operates at the cellular level. Developments in cancer prevention, screening, and therapy have saved millions of lives. Although there are still 1.5 million new cases of cancer diagnosed in the U.S. every year, the country now also has at least 11 million survivors of various types of cancer. But it’s important to remember that virtually all types of cancer are either aggressive at the onset, or eventually become aggressive.

In the case of breast cancer, there are now 2.5 million Americans who are living with the disease, with 230,000 new cases detected annually. There are two genes which have been associated with aggressive breast cancer: Her2 and Top2. Even though Herceptin, a $1.8 billion drug marketed by Roche, is an effective treatment for Her2, there are currently no approved therapies that target Top2. The Top2 gene encodes Topoisomerase II, an enzyme that unwinds DNA and is required for cell proliferation. Overexpression of Topoisomerase II allows the cell to divide more rapidly and as a result become more aggressive. It has been associated with breast, prostate, colon, lung, and other deadly cancers. Inhibition of Top2 activity is critical to treat multi-drug resistant breast cancer and other types of aggressive cancer, such as small-cell lung cancer.

Adva-27a, lead compound of Sunshine Biopharma, if approved, will be the only Topoisomerase II inhibitor on the market. Shown to be 16 times more effective at killing multi-drug resistant breast cancer cells than Etoposide, the most commonly used drug, Adva-27a can be used to treat other Top2 positive cancer types, such as lung, prostate, colon, stomach, and ovarian cancer. As the only Top2 inhibitor, and since it could help terminally ill patients, Adva-27a is likely to be granted fast-track designation.

For additional information, visit the company’s websites at www.SunshineBiopharma.com

About QualityStocks:

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: